Literature DB >> 25900964

Herpes zoster complicating bortezomib therapy.

Kamal Kant Sahu, Subhash Chander Varma1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25900964      PMCID: PMC4418166          DOI: 10.4103/0971-5916.155599

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
A 62 year old female patient with multiple myeloma was on follow up in the Haematology clinic, department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, and was receiving bortezomib based chemotherapy given on days 1, 4, 8, and 11 of 35-day cycle. After two such cycles in June 2013, she started developing painful skin lesions on right D9-10 dermatome. On examination erythematous, crusted superficial erosions with a few vesicular lesions were present (Figs A, B). Tzanck smear showed multinucleated giant cells confirming the diagnosis of herpes zoster (Figs C, D). It was found that despite advice she did not take acyclovir prophylaxis during chemotherapy which led to this complication. She was given oral valganciclovir 1 g thrice a day for 10 days. Unfortunately, she was lost to follow up. There are theories which explain increased susceptibility of patients on bortezomib to herpes infection12. Considering two earlier studies34 and our case, it is emphasised that acyclovir prophylaxis should be used during bortezomib treatment.
Figs

A, B. Well defined erythematous, crusted erosions with a few vesicular lesions (indicated by black arrows in (B) in a linear pattern over the right D 9-10 dermatome. Figs C, D. Light microscopy using tzanck smear and stained with Wright-Giemsa stain showing giant cells.

A, B. Well defined erythematous, crusted erosions with a few vesicular lesions (indicated by black arrows in (B) in a linear pattern over the right D 9-10 dermatome. Figs C, D. Light microscopy using tzanck smear and stained with Wright-Giemsa stain showing giant cells.
  4 in total

1.  Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.

Authors:  Tomohiro Aoki; Takahiro Nishiyama; Nobuhiko Imahashi; Kunio Kitamura
Journal:  Jpn J Clin Oncol       Date:  2011-05-25       Impact factor: 3.019

2.  Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.

Authors:  Abhisek Swaika; Aneel Paulus; Kena C Miller; Taimur Sher; Nikolaos G Almyroudis; Donna Ball; Margaret Wood; Aisha Masood; Kelvin Lee; Asher A Chanan-Khan
Journal:  J Support Oncol       Date:  2012-01-04

3.  Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.

Authors:  Eric Vickrey; Sharon Allen; Jayesh Mehta; Seema Singhal
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

Review 4.  Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

Authors:  Andreas A Argyriou; Gregoris Iconomou; Haralabos P Kalofonos
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

  4 in total
  5 in total

1.  Acute generalised skin rash secondary to the Nystatin Oral Suspension.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Amos Lal; Rahul Gandhi
Journal:  BMJ Case Rep       Date:  2019-05-27

2.  From Oncologist's Desk: Hemato-Oncological Aspect of Using Vaporizers, E-Cigarettes, and Other Electronic Nicotine Delivery Systems (ENDS).

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Amos Lal; Ahmad Daniyal Siddiqui; George M Abraham
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-06       Impact factor: 0.900

Review 3.  Trajectory of the COVID-19 pandemic: chasing a moving target.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Amos Lal
Journal:  Ann Transl Med       Date:  2020-06

Review 4.  Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV).

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Amos Lal
Journal:  Ann Transl Med       Date:  2020-03

5.  Latest updates on COVID-2019: A changing paradigm shift.

Authors:  Kamal Kant Sahu; Amos Lal; Ajay Kumar Mishra
Journal:  J Med Virol       Date:  2020-03-20       Impact factor: 2.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.